2016年7月
Persistently high exhaled nitric oxide and loss of lung function in controlled asthma
ALLERGOLOGY INTERNATIONAL
- ,
- ,
- ,
- ,
- 巻
- 65
- 号
- 3
- 開始ページ
- 266
- 終了ページ
- 271
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1016/j.alit.2015.12.006
- 出版者・発行元
- JAPANESE SOCIETY ALLERGOLOGY
Backgrounds: It remains unclear whether a persistently high exhaled nitric oxide fraction (FeNO) in patients with controlled asthma is associated with the progressive loss of lung function.
Methods: This was a 3-year prospective study. We examined the changes in pre- and post-bronchodilator forced expiratory volume in 1 s (FEV1) and FeNO in 140 patients with controlled asthma. We initially determined the FeNO cut-off point for identifying patients with a rapid decline in FEV1 (>40 mL/yr). Next, a total of 122 patients who maintained high or non-high FeNO were selected, and the associations between the FeNO trend and changes in FEV1 and bronchodilator response (BDR) were investigated.
Results: A FeNO level >40.3 ppb yielded 43% sensitivity and 86% specificity for identifying patients with a rapid decline in FEV1. Patients with persistently high FeNO had higher rates of decline in FEV1 (42.7 +/- 37.5 mL/yr) than patients with non-high FeNO (16.7 +/- 31.5 mL/yr) (p < 0.0005). The changes in BDR from baseline to the end of the study, in patients who had high or non-high levels of FeNO were -0.8% and 0.1%, respectively (p < 0.01). In a multivariate analysis adjusted by age, body mass index, asthma control, blood eosinophil numbers, and FEV1% of predicted, a FeNO level of >= 40 ppb was independently associated with an accelerated decline in FEV1 (p < 0.05).
Conclusions: This study suggests that FeNO is potentially valuable tool for identifying individuals who are at risk of a progressive loss of lung function among patients with controlled asthma. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.
Methods: This was a 3-year prospective study. We examined the changes in pre- and post-bronchodilator forced expiratory volume in 1 s (FEV1) and FeNO in 140 patients with controlled asthma. We initially determined the FeNO cut-off point for identifying patients with a rapid decline in FEV1 (>40 mL/yr). Next, a total of 122 patients who maintained high or non-high FeNO were selected, and the associations between the FeNO trend and changes in FEV1 and bronchodilator response (BDR) were investigated.
Results: A FeNO level >40.3 ppb yielded 43% sensitivity and 86% specificity for identifying patients with a rapid decline in FEV1. Patients with persistently high FeNO had higher rates of decline in FEV1 (42.7 +/- 37.5 mL/yr) than patients with non-high FeNO (16.7 +/- 31.5 mL/yr) (p < 0.0005). The changes in BDR from baseline to the end of the study, in patients who had high or non-high levels of FeNO were -0.8% and 0.1%, respectively (p < 0.01). In a multivariate analysis adjusted by age, body mass index, asthma control, blood eosinophil numbers, and FEV1% of predicted, a FeNO level of >= 40 ppb was independently associated with an accelerated decline in FEV1 (p < 0.05).
Conclusions: This study suggests that FeNO is potentially valuable tool for identifying individuals who are at risk of a progressive loss of lung function among patients with controlled asthma. Copyright (C) 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.alit.2015.12.006
- ISSN : 1323-8930
- eISSN : 1440-1592
- PubMed ID : 26822895
- Web of Science ID : WOS:000379507500008